ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1405

A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis

Ana Bento da Silva1, Floris A. van Gaalen1, Robert Landewé2, Manouk de Hooge3, Mary Lucy Marques4, Miranda van Lunteren1, Liese de Bruin1, Gizem Ayan5, Xenofon Baraliakos6, Monique Reijnierse7, Jürgen Braun8, Désirée Van Der Heijde1 and Sofia Ramiro9, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 3Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 5Ankara Research and Training Hospital, Ankara, Turkey, 6Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 7Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 8Ruhr-University, Bochum, Germany; and Rheumatologische Versorgungszentrum (RVZ) Steglitz, Berlin, Germany, 9Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2025

Keywords: Imaging, Measurement Instrument, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The computed tomography (CT) syndesmophyte score (CTSS) has shown to be more sensitive in capturing spinal structural damage progression in axial SpA (axSpA), compared to the current gold standard, the modified Stoke Ankylosis Spondylitis Spine Score (mSASSS) (de Koning A et al, Ann Rheum Dis 2018). Additionally, assessing facet joint ankylosis (FJA) on CT seems promising in further detecting progression (Stal R et al, Rheumatology 2020). We investigated whether a score combining syndesmophytes and FJA is more sensitive than CTSS for assessing spinal damage progression in axSpA.

Methods: Data from the Sensitive Imaging in Ankylosing Spondylitis cohort were used, including axSpA patients fulfilling the modified New York criteria and with ≥1 syndesmophyte. Conventional radiography (CR) and low-dose computed tomography (ldCT) of the spine were performed at baseline and 2 years (2Y) and scored by 3 (CR) or 2 (ldCT) central readers, blinded for time order. Syndesmophytes were assessed on CR and ldCT by the mSASSS and CTSS, respectively (Figure 1). The presence of FJA was evaluated on ldCT with the facet ankylosis score (FAS) on 19 facet joints (levels C5-T2 excluded due to poor visibility). The total mSASSS, CTSS and FAS were calculated per reader at each timepoint. Three versions of a combined score of syndesmophytes and FJA were proposed and computed by adding the CTSS and FAS while giving equal weight to both components (CT facet ankylosis syndesmophyte spine score A [CTFASSS-A]), 50% (CTFASSS-B) or 100% more weight to FAS (CTFASSS-C). Change scores were calculated per reader by subtracting the baseline from the 2Y score and then averaged across readers. The number of patients with positive and negative change as well as net change >0 and >0.5 were calculated for each score and compared. The total number of new or growing syndesmophytes and new FJA were calculated per reader and then averaged across readers.

Results: Forty-eight patients were included: mean (SD) age of 49 (9.7) years, 85% male, 81% HLA-B27+. Between baseline and 2Y, progression of spinal damage was observed as assessed by all scores: mean (SD) mSASSS 18.3 (14.3) vs 20.4 (15.1), CTSS 161.6 (127.1) vs 179.5 (132.3), FAS 8.2 (9.8) vs 9.4 (10.2). CTFASSS changed from 169.8 (134.5) (CTFASSS-A), 174.0 (138.4) (CTFASSS-B) and 178.1 (142.3) (CTFASSS-C) at baseline to 188.9 (140.0), 193.6 (143.9) and 198.3 (147.9) at 2Y, respectively.After 2Y, CTFASSS-A, CTFASSS-B and CTFASSS-C detected any net change in a higher percentage of patients compared to CTSS (96% vs 83%) and, most notably, to mSASSS (96% vs 46%) and FAS (96% vs 48%) (Table 1A). Moreover, considering all 48 patients, 472 new or growing syndesmophytes and 73 new FJA were detected on ldCT, denoting that the combined score captured 1.15 times more new bone formation than CTSS (545 vs 472 new lesions) (Table 1B).

Conclusion: A combined score assessing syndesmophytes and FJA captures more spinal structural damage progression in axSpA than assessing syndesmophytes alone. With respect to sensitivity to change, all CTFASSS proposals performed similarly, with the simple addition of CTSS and FAS (CTFASSS-A) being the most straightforward approach. However, further validation will define which is the best combination.

Supporting image 1Figure 1. Schematic representation to guide the calculation of the mSASSS (A), CTSS (B), FAS (C) and CTFASSS (D)

Supporting image 2Table 1. Number of axSpA patients with spinal structural damage progression on low-dose computed tomography (n=48)


Disclosures: A. Bento da Silva: None; F. van Gaalen: AbbVie, 2, BMS, 2, Eli Lilly, 2, Jacobus Stichting, 5, MSD, 2, Novartis, 2, 5, Stichting ASAS, 5, Stichting vrienden van Sole Mio, 5, UCB, 5; R. Landewé: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, Joint Imaging BV, 12, Director, Novartis, 2, Pfizer, 2, Rheumatology Consultancy BV, 12, Director, UCB, 2; M. de Hooge: UCB pharma, 2; M. Marques: Novartis, 2, 6; M. van Lunteren: None; L. de Bruin: None; G. Ayan: None; X. Baraliakos: AbbVie, 2, 5, 6, 12, Paid Instructor, Advanz, 2, 6, 12, Paid instructor, Alexion, 2, 6, 12, Paid instructor, Alphasigma, 2, 6, 12, Paid instructor, Amgen, 2, 6, 12, Paid instructor, BMS, 2, 6, 12, Paid instructor, Celgene, 6, Celltrion, 2, 5, 6, 12, Paid instructor, Cesas, 2, 6, 12, Paid instructor, Chugai, 2, 6, Clarivate, 6, 12, Paid instructor, Galapagos, 2, 6, 12, Paid instructor, J&J, 2, 6, 12, Paid instructor, Janssen, 5, Lilly, 2, 6, 12, Paid instructor, Merck, 6, MoonLake, 2, 5, 6, 12, Paid instructor, MSD, 2, Novartis, 2, 5, 6, 12, Paid instructor, Peervoice, 2, 6, 12, Paid instructor, Pfizer, 2, 6, 12, Paid instructor, Roche, 2, 6, 12, Paid instructor, Sandoz, 2, 6, 12, Paid instructor, Springer, 2, 6, 12, Paid instructor, Stada, 2, 6, 12, Paid instructor, Takeda, 2, 6, 12, Paid instructor, UCB, 2, 6, 12, Paid instructor, Zuellig, 2, 6, 12, Paid instructor; M. Reijnierse: None; J. Braun: None; D. Van Der Heijde: AbbVie, 2, Alfasigma, 2, Annals of the Rheumatic Diseases, 12, Associate editor, ArgenX, 2, Bristol Myers Squibb, 2, Eli Lilly and Company, 2, Grey-Wolf Therapeutics, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Journal of Rheumatology, 12, Editorial board member, Novartis, 2, Pfizer, 2, RMD Open, 12, Editoral board member, Takeda, 2, UCB, 2; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, 5, Galapagos/Alfasigma, 2, 5, Janssen, 2, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Bento da Silva A, van Gaalen F, Landewé R, de Hooge M, Marques M, van Lunteren M, de Bruin L, Ayan G, Baraliakos X, Reijnierse M, Braun J, Van Der Heijde D, Ramiro S. A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-combined-score-of-syndesmophytes-and-facet-joint-ankylosis-improves-sensitivity-to-spinal-structural-damage-progression-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-combined-score-of-syndesmophytes-and-facet-joint-ankylosis-improves-sensitivity-to-spinal-structural-damage-progression-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology